Abstract
Oxygen is critical to the prevention of hypoxemia-induced morbidity and mortality; yet, access remains inadequate in most low- and middle-income countries (LMICs) despite billions of dollars spent over decades to increase supply. We present a new method for supplemental oxygen delivery whereby the OXFO System (OXFO Corporation, Boston, MA, USA) converts pressurized oxygen to ambient pressure for patient inhalation on demand at a fixed concentration across fluctuations in respiratory rate or tidal volume. This study’s primary aims were to examine the oxygen volume savings and test the non-inferiority of mean peripheral oxygen saturation ($SpO_2$) with the OXFO System (OXFO Condition) compared to conventional continuous flow (Standard Condition) in a clinical population of oxygen-dependent hospitalized adults.
Introduction
Supplemental oxygen is a fundamental medicine, yet the COVID-19 pandemic underscored a persistent global health crisis: the lack of reliable oxygen access in low- and middle-income countries (LMICs). A primary driver of this scarcity is the inherent wastefulness of standard delivery methods. Continuous flow systems dispense oxygen throughout the entire respiratory cycle, meaning a significant portion of the gas is lost to the environment during exhalation.
While various oxygen-conserving devices (OCDs) like reservoir cannulas or pulse-demand systems exist, they often suffer from an "efficiency-effectiveness" trade-off. These devices frequently lose performance at higher flow rates or cause patient discomfort due to the pressurized nature of the delivery. The OXFO System was developed to provide high-efficiency conservation without sacrificing patient oxygenation, even at higher clinical doses.
The OXFO System Mechanism
The OXFO System represents a novel approach to oxygen conservation by decoupling delivery pressure from inhalation. Unlike traditional systems that deliver pressurized gas, the OXFO device converts pressurized oxygen into an internal ambient-pressure reservoir bag.
As shown in the internal schematic, infrared sensors monitor the volume of this reservoir bag. When a patient inhales and the bag collapses, a solenoid valve opens to refill it. This "on-demand" delivery at ambient pressure allows patients to draw exactly the volume they need with each breath, a process the authors compare to drinking from a glass with a straw rather than a pressurized hose.
Methods
To validate this technology, researchers conducted a single-visit, randomized, crossover, non-inferiority study at a hospital in Medellín, Colombia. The study included 19 oxygen-dependent hospitalized adults (ages 43–70) with primary diagnoses including COPD, Congestive Heart Failure (CHF), and pneumonia. All patients were already prescribed supplemental oxygen at doses of at least 2 L/min.
Subjects were randomized to receive either the OXFO Condition or the Standard Condition (continuous flow) first. For each condition, oxygen was titrated to reach a target therapeutic $SpO_2$ (e.g., 94% for non-hypercapnic patients). Following titration, physiological data and oxygen consumption were recorded for 20 minutes. The primary endpoints were the ratio of oxygen volume dispensed and the mean $SpO_2$ levels.
Results
The clinical trial revealed massive efficiency gains. The OXFO System used a mean of only 7.7% (SD=5.4%) of the oxygen required by the Standard Condition ($P < 0.001$). This represents a nearly 13-fold reduction in oxygen consumption. Notably, this efficiency remained robust across the entire tested range (up to 6 L/min), maintaining a ~92% savings ratio regardless of the dose.
Regarding clinical efficacy, the OXFO System demonstrated clear non-inferiority. The mean $SpO_2$ for the OXFO Condition was 91.07% (SD=2.20%) compared to 91.35% (SD=1.62%) for the Standard Condition. The difference was well within the pre-defined non-inferiority margin of -2.8% ($P < 0.001$). Furthermore, there were no significant differences in patient-reported dyspnea (shortness of breath) or discomfort, suggesting the system is well-tolerated.
Discussion and Conclusion
The OXFO System successfully maintains clinical oxygenation while drastically reducing the volume of gas required. The observed 13x savings exceeded initial bench-test predictions of 5x, likely because the device allows for more precise titration to a patient's actual physiological needs in a clinical setting compared to the "blunt instrument" of continuous flow.
While the study was limited by its short duration (20 minutes) and single-center design, the results are promising for oxygen-scarce environments. By extending the life of oxygen cylinders by an order of magnitude, such technology could significantly reduce the logistical burden and costs of oxygen delivery in LMICs. Future research should focus on long-term use, including sleep and physical activity, to confirm the system's utility in broader clinical and home-care contexts.
Summary updated